HLA Health HourMedicaid & MedicareInsuranceMental HealthNutritionFind a ProviderHealth JobsProvider Corner
ALERTS (5) ▾
Healthcare Markets
UNH 340.01 ▼0.02%ELV 403.00 ▲1.93%CI 275.00 ▲1.29%CVS 80.97 ▲0.11%HUM 385.25 ▼1.25%CNC 63.94 ▲0.24%MOH 198.50 ▲0.00%HCA 475.00 ▼0.22%THC 263.00 ▼0.07%UHS 179.43 ▼0.12%LLY 1347.00 ▼0.13%PFE 27.40 ▼0.11%JNJ 270.93 ▲0.09%MRK 134.43 ▲0.48%ABBV 286.50 ▼0.35%NVO 37.84 ▲0.08%MDT 99.52 ▼0.55%ABT 104.33 ▲0.99%ISRG 400.17 ▲0.28%XLV 176.86 ▼0.28%Delayed quotes. Not investment advice.UNH 340.01 ▼0.02%ELV 403.00 ▲1.93%CI 275.00 ▲1.29%CVS 80.97 ▲0.11%HUM 385.25 ▼1.25%CNC 63.94 ▲0.24%MOH 198.50 ▲0.00%HCA 475.00 ▼0.22%THC 263.00 ▼0.07%UHS 179.43 ▼0.12%LLY 1347.00 ▼0.13%PFE 27.40 ▼0.11%JNJ 270.93 ▲0.09%MRK 134.43 ▲0.48%ABBV 286.50 ▼0.35%NVO 37.84 ▲0.08%MDT 99.52 ▼0.55%ABT 104.33 ▲0.99%ISRG 400.17 ▲0.28%XLV 176.86 ▼0.28%Delayed quotes. Not investment advice.
Saturday, November 21, 2026
Edition
HELPHEALTHLINK BRIEF
HLA Network News
HealthLink of America
HEALTHLINK OF AMERICA NEWS / RESOURCES
NORTH CAROLINA HEALTH PLANS
NC MedicaidMedicareBlue Cross NCHealthy BlueAmeriHealth Caritas NCCarolina Complete HealthUnitedHealthcare Community PlanWellCare of NCAlliance HealthTrillium Health ResourcesVaya PartnersAetnaHumanaCigna
All plans ›
ADVERTISEMENT
ADVERTISE WITH HLA NETWORK NEWS
Reach patients, families and providers in their city.
Health brands only. Banner, sidebar, section, directory, jobs and HealthLink Brief placements.
GET THE MEDIA KIT
Health Markets · national

Pancreatic cancer drug shows tumor shrinkage in early trial results

A combination treatment shrank tumors in patients with advanced pancreatic cancer that had spread, early trial data shows.

A drug called daraxonrasib combined with chemotherapy caused substantial tumor shrinkage in patients with pancreatic cancer that had spread to other parts of the body, according to results from a Phase I/II clinical trial presented at a cancer research conference in Barcelona, Spain.

The trial tested the combination in patients who had not previously received treatment for metastatic disease (cancer that has spread). A doctor at Memorial Sloan Kettering Cancer Center said the results were encouraging because the treatment not only shrank tumors but also helped control the disease for longer periods.

Pancreatic cancer is difficult to treat, especially when it has already spread. According to the trial information, most patients with metastatic pancreatic cancer treated with standard chemotherapy alone survive between eight and 11 months, and only 3% are alive five years after diagnosis. Tumor shrinkage occurs in only 23% to 42% of patients on chemotherapy, and most tumors begin growing again after five to six months.

The trial results suggest the new combination may help more patients see tumor shrinkage and maintain disease control longer than chemotherapy alone, though the research is still in early stages.

What it means in Raleigh

RALEIGH HEALTH SYSTEM
State agency: NC Department of Health and Human Services (NCDHHS)
Behavioral health: Alliance Health (LME/MCO for Wake, Durham, Johnston, Orange, Cumberland, Mecklenburg)
Medicaid plans: NC Medicaid Standard Plans: AmeriHealth Caritas NC, Carolina Complete Health, Healthy Blue, UnitedHealthcare Community Plan, WellCare of NC. Tailored Plans: Alliance Health, Trillium Health Resources, Vaya Partners (Vaya Health + Partners Health Management, merged 2026).
Major insurers: Blue Cross NC, Aetna, Cigna, UnitedHealthcare, Humana
Plan lists change; confirm with your plan or the state agency.

Sources

Not medical advice. HLA Network News reports health news. Talk to your doctor or care team about your own care. In a crisis, call or text 988. In an emergency, call 911.
ADVERTISEMENT · SIDEBAR 300x250
Reach health readers here. Advertise with HLA